PALLIATIVE CARE & MANAGEMENT of SYMPTOMS in ADVANCED LIVER DISEASE: AN EXPERT REVIEW.

IF 3.8 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-04-08 DOI:10.1080/17474124.2025.2491529

Jessica L Allen, Richard K Sterling

{"title":"PALLIATIVE CARE & MANAGEMENT of SYMPTOMS in ADVANCED LIVER DISEASE: AN EXPERT REVIEW.","authors":"Jessica L Allen, Richard K Sterling","doi":"10.1080/17474124.2025.2491529","DOIUrl":null,"url":null,"abstract":"Introduction: Chronic liver disease (CLD) is a leading cause of death worldwide. End stage liver disease (ESLD) causes a rapid and progressive decline in health and quality of life (QOL) and creates significant suffering and burdens for patients, families and health systems alike. These patients have significant physical, psychological and complex social needs that benefit from the support of an interdisciplinary palliative care (PC) team.Areas covered: This review of the English literature analyzes general palliative care principles for the CLD and ESLD populations including factors affecting QOL and review of symptom management per AASLD and AGA Guidelines. We have also reviewed the impacts of palliative support on QOL, caregiver burden, and healthcare related outcomes.Expert opinion: ESLD causes significant suffering and burdens for patients, families and healthcare systems. PC is an essential component of ESLD care and improves QOL, caregiver burdens and shows benefits of reduced health care costs and aggressive care at end of life. Provider and community misunderstanding or inexperience of PC is often a barrier to PC involvement. There is a clear lack of standardization in medical training and lack of clear guidelines on when to involve PC in the ESLD population that must be addressed.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Gastroenterology & Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474124.2025.2491529","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Chronic liver disease (CLD) is a leading cause of death worldwide. End stage liver disease (ESLD) causes a rapid and progressive decline in health and quality of life (QOL) and creates significant suffering and burdens for patients, families and health systems alike. These patients have significant physical, psychological and complex social needs that benefit from the support of an interdisciplinary palliative care (PC) team.

Areas covered: This review of the English literature analyzes general palliative care principles for the CLD and ESLD populations including factors affecting QOL and review of symptom management per AASLD and AGA Guidelines. We have also reviewed the impacts of palliative support on QOL, caregiver burden, and healthcare related outcomes.

Expert opinion: ESLD causes significant suffering and burdens for patients, families and healthcare systems. PC is an essential component of ESLD care and improves QOL, caregiver burdens and shows benefits of reduced health care costs and aggressive care at end of life. Provider and community misunderstanding or inexperience of PC is often a barrier to PC involvement. There is a clear lack of standardization in medical training and lack of clear guidelines on when to involve PC in the ESLD population that must be addressed.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Gastroenterology & Hepatology GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

6.80

自引率

2.60%

发文量

审稿时长

6-12 weeks

期刊介绍： The enormous health and economic burden of gastrointestinal disease worldwide warrants a sharp focus on the etiology, epidemiology, prevention, diagnosis, treatment and development of new therapies. By the end of the last century we had seen enormous advances, both in technologies to visualize disease and in curative therapies in areas such as gastric ulcer, with the advent first of the H2-antagonists and then the proton pump inhibitors - clear examples of how advances in medicine can massively benefit the patient. Nevertheless, specialists face ongoing challenges from a wide array of diseases of diverse etiology.